The Gastroenterology & Hepatology seeks adults over age 18 with NASH for a research study. The purpose of the study is see if an investigational drug (lanifibranor) is effective at reducing fibrosis.

Study involves taking an experimental medicine/placebo by mouth daily, blood draws, liver biopsy, fibroscan, EKGs, optional DEXA scans, and daily weight measurements. Study involves at least 22 visits to UVA over approximately 7 years.

Study-related exams, tests and experimental medication provided free of charge.

The Gastroenterology and Hepatology seeks adults ages 18 to 75 with Primary Biliary Cholangitis (PBC) for a research study. The purpose of the study is to see if a new drug (sarogliazar) is effective at improving the lab results for patients with PBC.

Study involves taking an experimental medicine/placebo daily, blood draws, fibroscan, EKGs, and abdominal ultrasounds. This study involves at least 15 visits at UVA over approximately 59 weeks. Each visit lasting about 1 1/2 hours.

Study-related (insert exams, tests and experimental medication) provided free of charge.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have Unresectable non-small cell lung cancer (NSCLC). The purpose of this study is to find out if adding a study drug (MEDI4736 [durvalumab]) during chemotherapy and radiation therapy is better or worse than the usual approach for your advanced non-small cell lung cancer. The usual approach is defined as chemotherapy and radiation given together followed by the MEDI4736 (durvalumab) for one year.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have pancreatic cancer. This study is being done to learn more about adding the experimental drugs AZD0171 and durvalumab to the current treatment of chemotherapy (nab-paclitaxel and gemcitabine).

The total treatment duration is unknown as you will receive the study drug as long as your disease status does not worsen or no other reasons for stopping occur.

UVA Health System, Department of Internal Medicine, Division of Endocrinology is conducting a clinical research study. We want to learn more about how exercise training affects blood vessels in skeletal and cardiac muscle in persons with Type 2 diabetes and individuals who are overweight but otherwise healthy. You may be eligible if you are 30-55 years of age and either have Type 2 diabetes or are overweight but otherwise healthy. You must be a nonsmoker and a non-exerciser.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have EGFR Mutant non-small cell lung cancer. The purpose of this study is to test if the combination of CB-839 HCl (telaglenastat) and AZD9291 is safe in patients with non-small cell lung cancer.

If you join this study you will receive CB-839 HCl (telaglenastat) and AZD9291. The total treatment duration is unknown as you will receive the study drugs as long as your disease status does not worsen or no other reasons for stopping occur.

The University of Virginia’s Joint Emerging Diseases Initiative team seeks people age 30 years and older with a recent positive COVID test who are experiencing symptoms for a research study. The purpose of the study is to see if re-purposed medications can help people with mild to moderate COVID-19 feel better faster and stay out of the hospital. These medications are FDA approved for use in other illnesses and are being studied for their effectiveness in treating COVID.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). If you join this study, you will receive an investigational drug called Eltanexor. The trial will investigate the investigational drug by testing its safety and how your body reacts to the study drug. Each treatment cycle is 28 days. If you have AML, you’ll take the study drug 7 days per week for 21 days each cycle. If you have MDS, you will take the study drug 5 days per week during the entire cycle.

The University of Virginia Cancer Center is conducting a two phase clinical research study for patients who are adults ages 18 and over, have a solid tumor cancer (not including melanoma and hepatocellular carcinoma) in Phase I and pancreatic, ovarian, or cholangiocarcinoma cancer in Phase 2, and have already tried other therapies to treat their cancer.

The Center for Diabetes Technology seeks adults ages 18 and up with type 1 diabetes for a research study. The purpose of this study is to test different ways CGM data can be used to help manage your diabetes.

You may be eligible for this study if you have had type 1 diabetes for at least one year and using insulin for at least one year, and your A1c is between 6.0% - 11%.